Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma.
Myra E van LindeMariette LabotsCyrillo G BrahmKoos E HovingaPhilip C De Witt HamerRichard J HoneywellRichard de Goeij-de HaasAlexander A HennemanJaco C KnolGodefridus J PetersHenk DekkerSander R PiersmaThang V PhamWilliam Peter VandertopConnie R JiménezHenk M W VerheulPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Achieved tumor sunitinib concentrations in patients with GBM are higher than in plasma, but lower than reported for other tumor types and insufficient to significantly inhibit tumor cell growth in vitro. Therefore, alternative TKI dosing to increase intratumoral sunitinib concentrations might improve clinical benefit for patients with GBM. In parallel, a complex profile of kinase activity in GBM was found, supporting the potential of (phospho)proteomic analysis for the identification of targets for (combination) treatment.